Researchers found that ArfGAP2 appears to play a key role in both normal immune responses and harmful overactivity.

Annovis made significant progress by advancing the buntanetap program, successfully completing two clinical trials—Phase 2/3 AD and Phase 3 PD. Both studies yielded promising results, reinforcing ...

ALZcure is pioneering blockchain-powered funding for Alzheimer's research through Decentralized Science (DeSci). Built on ...

In an international research collaboration involving the University Medical Center Göttingen (UMG), researchers have produced ...

The geroscience hypothesis holds that targeting molecular pathways that drive aging can give us more healthy years. Evidence ...

IGC Pharma has added Hamilton Health Sciences (HHS) in Canada as a new clinical site for its ongoing, randomised Phase II CALMA trial of IGC-AD1 to treat agitation in Alzheimer’s disease. This ...

With documented swimming speeds of up to 46 miles per hour, mako sharks represent the world’s fastest elasmobranch species.

As part of this Research Topic, we are hosting a webinar and public Q&A featuring Prof. Michael Lutz (Duke University) and Dr ...

Planned single, pivotal Phase 2/3 clinical trial, if positive, acceptable for Biological License Application (BLA) submission for Alzheimer’s ...

Originally launched in 1986 by epidemiologist Dr. David A. Snowdon, the study has moved between several institutions and is now housed at the Glenn Biggs Institute for Alzheimer’s and ...

A groundbreaking peer-reviewed Thought Leaders Invited Review article in Brain Medicine (Genomic Press, New York) explores how CD2-associated protein (CD2AP) contributes to Alzheimer's disease (AD), ...

Inflammation may be at the core of cognitive decline as recent studies offer clues on how herpes simplex virus-1, antibiotics, antivirals, and vaccines may have different effect on dementia risk.